Inocras
PrivateLast Round
Series B
Extension
Aug 3, 2026
Total Funding Raised
$89M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Inocras operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series B Extension round in August 2026.
Inocras is a biotechnology company that provides an AI-driven platform offering whole genome insights to enable personalized care in cancer and rare diseases.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Biotechnology, Healthcare Analytics, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Usage-Based SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Inocras Comparables
Compare Inocras with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Predicine | 84% | |
| Variantyx | 83% | |
| Strata Oncology | 79% |
For institutional investors. Book with your work email.
Inocras Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Aug 3, 2026 | ||||
| Strategic | Jul 1, 2026 | ||||
| Series B Extension | Nov 1, 2023 | ||||
| Series B | Apr 30, 2022 | ||||
| Series A | Dec 1, 2020 | ||||
Series A | Nov 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Inocras Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Woori Investment & Securities | Series B Extension |
| InterVest | Series B Extension, Series B |
| DSC Investment | Series A, Series B Extension, Series B, Seed |
| Korea Investment & Securities | Series B Extension |
| Paratus Investment | Series A, Series B |
| Samsung Venture Investment | Series B Extension |
| Schmidt | Series A, Series B, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 3, 2026
$31M round with participation from Dt& Investment and DSC Investment.
- Jul 1, 2026
Raised a strategic round with Aimed Bio Inc.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- expands_offices_inAug 4, 2026
Inocras Inc. intends to expand its commercial and operational infrastructure in the United States to bring its whole-genome sequencing and bioinformatics platform to the U.S. market.
For institutional investors. Book with your work email.
Inocras Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Inocras's valuation, stock price, and market status.
Is Inocras a public or private company?
Inocras is a private company.
What is the current stock price of Inocras?
Inocras is a private company, so its shares have no public market price. Caplight tracks Inocras's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Inocras worth (valuation)?
Valuation information for Inocras is not publicly available.
Can I buy Inocras stock?
Inocras shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Inocras's last funding round?
Inocras's most recent funding round was Series B Extension on August 3, 2026.
Who are the main investors in Inocras?
Key investors in Inocras include Dunamu & Partners.
Will Inocras IPO soon?
No public IPO plans have been announced for Inocras.
How can I track Inocras secondary market activity?
Caplight tracks bids, offers, and trades in Inocras's shares on secondary markets.